Abstract
The clinical management of Crohn’s disease (CD) has evolved in recent years from symptom control to healing of mucosal lesions. Mucosal healing, induced and maintained by immunomodulators and/or biologicals, has been shown to alter the disease course in patients with CD. As a consequence, long-term disease outcomes have been dramatically improved, in particular since the introduction of anti-tumor necrosis factor (TNF) agents. CD patients with active inflammation (ileocolonic ulcers and/or increased C-reactive protein levels) benefit most from treatment with TNF antagonists. Since healing of the inflamed mucosa is now considered an important treatment goal, endoscopic monitoring is gradually entering routine practice. Therefore, the mucosal appearance will more and more influence the therapeutic decision making process. Mucosal healing has also become an end-point in therapeutic trials. We will summarize some of the fundamental issues regarding mucosal healing and discuss data to support its clinical relevance in the management of CD.
Keywords: Anti-tumor necrosis factor (TNF) agents, biologicals, Crohn’s disease (CD), immunomodulators, mucosal healing, long-term disease course, inflammation, endoscopic monitoring, clinical relevance, colonic CD.
Current Drug Targets
Title:Mucosal Healing in Crohn’s Disease: Relevance for Clinical Outcomes
Volume: 13 Issue: 10
Author(s): Mark Lowenberg and Geert D’Haens
Affiliation:
Keywords: Anti-tumor necrosis factor (TNF) agents, biologicals, Crohn’s disease (CD), immunomodulators, mucosal healing, long-term disease course, inflammation, endoscopic monitoring, clinical relevance, colonic CD.
Abstract: The clinical management of Crohn’s disease (CD) has evolved in recent years from symptom control to healing of mucosal lesions. Mucosal healing, induced and maintained by immunomodulators and/or biologicals, has been shown to alter the disease course in patients with CD. As a consequence, long-term disease outcomes have been dramatically improved, in particular since the introduction of anti-tumor necrosis factor (TNF) agents. CD patients with active inflammation (ileocolonic ulcers and/or increased C-reactive protein levels) benefit most from treatment with TNF antagonists. Since healing of the inflamed mucosa is now considered an important treatment goal, endoscopic monitoring is gradually entering routine practice. Therefore, the mucosal appearance will more and more influence the therapeutic decision making process. Mucosal healing has also become an end-point in therapeutic trials. We will summarize some of the fundamental issues regarding mucosal healing and discuss data to support its clinical relevance in the management of CD.
Export Options
About this article
Cite this article as:
Lowenberg Mark and D’Haens Geert, Mucosal Healing in Crohn’s Disease: Relevance for Clinical Outcomes, Current Drug Targets 2012; 13 (10) . https://dx.doi.org/10.2174/138945012802429688
DOI https://dx.doi.org/10.2174/138945012802429688 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer
Current Drug Targets Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Natural History of Ulcerative Colitis: Current Knowledge
Current Drug Targets Ethnic Differences in Pharmacogenetically Relevant Genes
Current Drug Targets MicroRNAs Contribute to Hepatocellular Carcinoma
Mini-Reviews in Medicinal Chemistry Evaluation of Cell-detaching Effect of EDTA in Combination with Oxaliplatin for a Possible Application in HIPEC After Cytoreductive Surgery: A Preliminary in-vitro Study
Current Pharmaceutical Design Update of QSAR & Docking & Alignment Studies of the DNA Polymerase Inhibitors
Current Bioinformatics Intraoperative Targeted Optical Imaging: A Guide towards Tumor-Free Margins in Cancer Surgery
Current Pharmaceutical Biotechnology Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience Is Biotechnological Next-Generation Therapeutics Promising Enough in Clinical Development to Treat Advanced Colon Cancer?
Current Pharmaceutical Biotechnology Epothilones: A Novel Class of Non-taxane Microtubule-stabilizing Agents
Current Pharmaceutical Design Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
Current Molecular Medicine Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry Gender Effects on Rat Metabolism of AMG 900, an Orally Available Small Molecule Aurora Kinase Inhibitor
Drug Metabolism Letters The Role of NF-κB Inhibitors in Cell Response to Radiation
Current Medicinal Chemistry Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Beyond Cox-Inhibition: ‘Side-Effects’ of Ibuprofen on Neoplastic Development and Progression
Current Pharmaceutical Design Novel Drugs for Neuroblastoma
Drug Design Reviews - Online (Discontinued) Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry